- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Angioprotector reduces the increased vascular permeability, increases the resistance of the capillary walls, improves microcirculation and the drainage function of lymphatic vessels, moderately reduces platelet aggregation and blood viscosity, increases the erythrocyte membrane elasticity. The action is associated to a certain extent with an increase in the activity of plasma kinins.
Rapidly absorbed in the gastrointestinal tract. The maximum plasma concentration is reached 6 hours after ingestion. Plasma protein binding is 20-25%. Practically does not penetrate the blood-brain barrier.
Excreted by the kidneys (about 50%) and through the intestines (about 50%) mostly unchanged for 24 hours, 10% - as metabolites. The half-life is 5 hours.
In very small quantities (0.4 mcg / ml after taking 1.5 g of the drug) excreted in breast milk.
Vascular lesions with increased fragility and permeability of capillaries (diabetic retinopathy and nephropathy) and other microangiopathies associated with various cardiovascular and metabolic diseases.
Venous insufficiency of varying severity and its consequences (precursory condition with symptoms of swelling of tissues, pain, paresthesias, congestive dermatosis; superficial phlebitis, varicose veins, trophic ulcers).
1 capsule contains the active ingredient: calcium dobesilate (in the form of calcium dobesilate monohydrate 521.51 mg) - 500.00 mg
excipients: corn starch - 25.164 mg, magnesium stearate - 8.326 mg;
Capsule number 0:
case: titanium dioxide E171 - 0.8640 mg, iron dye oxide yellow E172 — 0.1440 mg;
cap: iron dye black oxide E 172 - 0.1920 mg, indigo carmine dye E132 - 0.1728 mg, titanium dioxide E171 - 0.4800 mg, iron dye yellow oxide E172 - 0.5760 mg, gelatin to 96 mg.
No customer reviews for the moment.
Dosage and Administration
Orally, without chewing, during food.
Assign 500 mg 3 times a day for 2-3 weeks, then reduce the dose to 500 mg 1 time per day. In the treatment of retinopathy and microangiopathy, 500 mg is prescribed 3 times a day for 4-6 months, then the daily dose is reduced to 500 mg 1 time per day.
The course of treatment varies from 3-4 weeks to several months, depending on the therapeutic effect.
The classification of adverse reactions according to the frequency of development: often - 1-10%, infrequently - 0.1-1%, rarely - 0.01-0.1%, very rarely, including some cases - <0.01%.
Violations of the gastrointestinal tract. Rarely: nausea, diarrhea, vomiting.
Violations of the skin and subcutaneous tissue. Rarely: allergic reactions (itching, rash).
Common disorders. Rarely: fever, chills.
Disorders of the musculoskeletal and connective tissue. Seldom: arthralgia.
Violations of the blood and lymphatic system. In some cases: agranulocytosis. The reaction is reversible and disappears after cessation of therapy.
Hypersensitivity to calcium dobesilat or any component of the drug, peptic ulcer and 12 duodenal ulcer (in acute stage), bleeding from the gastrointestinal tract, kidney and liver disease, hemorrhage caused by anticoagulants; pregnancy (I term), child age (up to 13 years).
Cases of drug interaction of dobesilate calcium have not yet been identified.
Pregnancy and Lactation
Adequate and strictly controlled studies of the safety of use in pregnant and lactating women have not been conducted. Use of the drug is contraindicated in the first trimester of pregnancy. In the second and third trimesters of pregnancy, the drug is prescribed only for health reasons if the expected effect of the use exceeds the possible risk to the fetus.
When appointed during lactation, it is necessary to resolve the issue of discontinuing breastfeeding.
The drug can be prescribed prophylactically.
If agranulocytosis symptoms appear (fever, headache, chills, weakness, pain when swallowing, inflammation of the oral mucosa), you should immediately consult a doctor and perform a blood test.
Calcium dobesilate can influence the results of laboratory tests to determine the level of creatinine.
Influence on ability to drive vehicles and work with mechanisms
The drug does not adversely affect the ability to drive vehicles and work with mechanisms.
Cases of overdose were reported.
- Brand name: Doxy hem
- Active ingredient: Calcium dobesilate
- Dosage form: Capsules 500 mg. On 10 capsules in the blister from PVC / AL. On 3 blisters with the application instruction in a pack cardboard.
- Manufacturer: Hemofarm
- Calcium dobesilate attenuates vascular injury and the progression of diabetic retinopathy in streptozotocin-induced diabetic rats
- Determination of calcium dobesilate in human plasma using ion-pairing extraction and high-performance liquid chromatography
- Flow-injection biamperometric direct determination of calcium dobesilate in irreversible couple system
- An open trial of calcium dobesilate in patients with venous ulcers and stasis dermatitis
- Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy
- The value of calcium dobesilate in the treatment of diabetic retinopathy
- Editorial: The impact of calcium dobesilate on vascular endothelial dysfunction
- Antioxidant-angioprotective actions of calcium dobesilate in diabetic rats
- Involvement of nitric oxide in the inhibition of aortic smooth muscle cell proliferation by calcium dobesilate
- Prevention of oxidation and apoptosis in human peripheral blood mononuclear cells exposed to calcium dobesilate
- Study of calcium dobesilate in diabetic rats
- Effect of calcium dobesilate on the functional capabilities of mesenteric lymphatics in the guinea pig
- Influence of calcium dobesilate on the raised synthesis of basement membrane collagen in diabetic rats
- Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro
- Efficacy of calcium dobesilate in treating acute attacks of hemorrhoidal disease
- Effects of calcium dobesilate on glomerulus TIMP1 and collagen IV of diabetic rats
- Effect of calcium dobesilate on nephropathy in type 2 diabetic rats
- Risk of drug-induced agranulocytosis: the case of calcium dobesilate
- Agranulocytosis associated with calcium dobesilate
- Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study
- Electrochemical studies of calcium dobesilate and interaction with DNA
- Selective electrochemical sensing of calcium dobesilate based on an ordered mesoporous carbon-modified pyrolytic graphite electrode
- In vitro antioxidant properties of calcium dobesilate
- Calcium Dobesilate for the Treatment of Erectile Dysfunction in Men with Diabetes Mellitus